Previous close | 3.1200 |
Open | 3.1200 |
Bid | 2.5000 |
Ask | 3.5000 |
Strike | 0.50 |
Expiry date | 2024-12-20 |
Day's range | 3.1200 - 3.1200 |
Contract range | N/A |
Volume | |
Open interest | 14 |
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...
Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") and the Medicare Ambulatory Surgical Center ("ASC") payment system (the "Proposed Rule") as a qualifying product effective April 1, 2025. This Proposed Rule for payment within hospital outp
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.